Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A pooled analysis of 31 studies found that CAR T-cell therapy dramatically reduced disease activity in patients with systemic lupus erythematosus (SLE). Disease activity scores dropped sharply within months of treatment, and autologous CAR T-cell therapy outperformed the allogeneic approach. Researchers say the findings point to a "favorable safety profile," with most side effects being mild and manageable.
CAR T-cell therapy is making waves in lupus treatment. A pooled analysis of 31 clinical studies — presented at ACR Convergence — found that chimeric antigen receptor T-cell (CAR T) therapy consistently reduced disease activity in 243 patients with systemic lupus erythematosus (SLE) who had previously failed at least two immunosuppressants. Researchers called the improvements "extraordinary," with disease activity scores plummeting over just six months of follow-up.
Autologous CAR T-cell therapy (using the patient's own cells) came out on top, making patients more than twice as likely to achieve a disease activity score of zero compared to allogeneic therapy. The most common side effect was cytokine release syndrome (CRS), but the vast majority of cases were mild and manageable with conservative treatment.
By the Numbers:
Why it matters: SLE is a notoriously difficult autoimmune disease to treat, and many patients exhaust standard therapies. These findings suggest CAR T-cell therapy could offer a powerful, potentially disease-modifying option — with a manageable safety profile — bringing real hope to patients with few remaining options.